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Abstract
Background: A cholesterol-palmitoyl interaction has been reported to occur in the dimeric interface of the b2-
adrenergic receptor crystal structure. We sought to investigate whether a similar phenomenon could be observed
with μ-opioid receptor (OPRM1), and if so, to assess the role of cholesterol in this class of G protein-coupled
receptor (GPCR) signaling.
Results: C3.55(170) was determined to be the palmitoylation site of OPRM1. Mutation of this Cys to Ala did not
affect the binding of agonists, but attenuated receptor signaling and decreased cholesterol associated with the
receptor signaling complex. In addition, both attenuation of receptor palmitoylation (by mutation of C3.55[170] to
Ala) and inhibition of cholesterol synthesis (by treating the cells with simvastatin, a HMG-CoA reductase inhibitor)
impaired receptor signaling, possibly by decreasing receptor homodimerization and Gai2 coupling; this was
demonstrated by co-immunoprecipitation, immunofluorescence colocalization and fluorescence resonance energy
transfer (FRET) analyses. A computational model of the OPRM1 homodimer structure indicated that a specific
cholesterol-palmitoyl interaction can facilitate OPRM1 homodimerization at the TMH4-TMH4 interface.
Conclusions: We demonstrate that C3.55(170) is the palmitoylation site of OPRM1 and identify a cholesterol-
palmitoyl interaction in the OPRM1 complex. Our findings suggest that this interaction contributes to OPRM1
signaling by facilitating receptor homodimerization and G protein coupling. This conclusion is supported by
computational modeling of the OPRM1 homodimer.
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Background
A cholesterol-palmitoyl interaction at C7.68(341) has
been observed in the crystallographic dimeric interface of
transmembrane helix (TMH) 1 and Helix 8 in the b2-
adrenergic receptor (b2-AR) crystal structure [1]. Palmi-
toylation is a covalent attachment of palmitic acid to
cysteine residues of membrane proteins. Palmitoylation of
the rhodopsin sub-family of G protein-coupled receptors
(GPCRs) has been universally reported, and similar cho-
lesterol-palmitoyl interactions may exist within other
GPCRs. Sequence alignment has identified cysteine
residues in the carboxy termini as potential palmitoyla-
tion sites in about 78% of 74 GPCRs examined [2]. How-
ever, these cysteines are not the only palmitoylation sites.
For example, although rat μ-opioid receptor (OPRM1)
has two cysteines [C7.63(346) and C7.68(351)] in its C
terminus, mutation of these cysteines did not decrease
the palmitoylation of OPRM1 [3], suggesting that C3.55
(170) (the only other intracellular cysteine of rat OPRM1)
may be the palmitoylation site. Similarly, V1A vasopressin
receptor also has palmitoylation sites outside its C term-
inal domain [4]. Normally, palmitoylation facilitates the
membrane targeting and signaling of GPCRs [5]. For
instance, palmitoylation-dependent receptor-G protein
interaction is observed with both the b2-adrenergic recep-
tor and the M2 muscarinic acetylcholine receptor [6,7].
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Although there is no definitive answer as to how
receptor palmitoylation contributes to GPCR signaling,
the cholesterol-palmitoyl interaction at the b2-AR crys-
tallographic dimeric interface suggests that facilitation of
homodimerization may be one possible scenario.
Because of the enrichment of many GPCRs in lipid raft
(cholesterol-rich) microdomains in cell membranes [8],
cholesterol within such microdomains can be easily
incorporated into the receptor dimer. In addition,
because the interaction surface appears to be too small
for the GPCR monomer to interact with G proteins [9],
dimerization may facilitate G protein coupling. In fact,
dimerization of many GPCRs, including OPRM1 and
b2-AR, regulates receptor signaling [10].
In the work described here, we tested the hypothesis
that a specific cholesterol-palmitoyl interaction within
the OPRM1 signaling complex affects its signaling by
facilitating homodimerization and G protein coupling.
Cholesterol, an important component of lipid raft
microdomains on the cell membrane, is critical for
GPCR signaling [11], and the localization of some
GPCRs in lipid raft microdomains has been suggested to
contribute to downstream signaling [8]. For example,
OPRM1 locates in lipid raft microdomains on the cell
membrane in the absence of agonist [12]. Extraction of
cholesterol from cells disrupts the entirety of the lipid
raft microdomains and inhibits OPRM1 signal transduc-
tion in both morphine-induced adenylyl cyclase inhibi-
tion and ERK phosphorylation [12]. Thus, if a
cholesterol-palmitoyl interaction could be identified in
the interface of the OPRM1 homodimer, it would sug-
gest that cholesterol and cholesterol-enriched lipid raft
microdomains may be linked to receptor palmitoylation
during regulation of receptor signaling. Further, if the
involvement of receptor dimerization and G protein
coupling could be determined, this finding would extend
our understanding of the mechanisms that underlie
GPCR signaling.
We identified the palmitoylation site on OPRM1 and
examined the ability of the cholesterol-palmitoyl interac-
tion to contribute to receptor homodimerization, G pro-
tein coupling, and signaling. In addition, we developed a
computational model of OPRM1 to calculate the contri-
bution of the cholesterol-palmitoyl interaction to the
total interaction energy at the homodimer interface.
Results
Cys170 is the palmitoylation site of OPRM1
We used wild-type HEK293 cells (HEK) and
HEKOPRM1 cells (HEK cells heterologously expressing
OPRM1 with HA spliced at the amino terminus) to vali-
date the palmitoylation assay [13]. HA-tagged receptors
were precipitated with HA antibody and protein G agar-
ose. The following procedures were used to determine
receptor palmitoylation: 1) Free sulfhydryl groups in
precipitated receptors were blocked with N-ethylmalei-
mide (NEM). 2) Palmitoylated cysteines were hydrolyzed
with hydroxylamine. 3) Biotin was conjugated to the de-
palmitoylated cysteines in the immunoprecipitated
receptors with btn-BMCC (1-biotinamido-4- [4’- (malei-
midomethyl) cyclohexane carboxamido] butane). The
amount of biotin linked to the receptors was determined
by immunoblotting.
We observed intensive biotin labeling in the
HEKOPRM1 cells but not in the HEK cells, which sug-
gested that the palmitoylation we detected was specific
to OPRM1 (Figure 1a, Lanes 1-2). Since NEM was used
to block free sulfhydryl groups, the immunoreactivity of
biotin increased when the NEM step was omitted (Fig-
ure 1a, Lane 4). In addition, the immunoreactivity of
biotin decreased when the hydroxylamine step was
omitted (Figure 1a, Lanes 5) and no biotin was detected
when btn-BMCC was not used (Figure 1a, Lanes 6),
which confirmed that the assay was suitable for detect-
ing the palmitoylation of OPRM1. To further confirm
that the assay could be used to detect palmitoylation
specifically, we used 2-bromopalmitate (2-BP), a palmi-
toylation inhibitor, to block all palmitoylation. A low
level of receptor palmitoylation was observed when
HEKOPRM1 cells were pretreated with 2-BP for 12 h
(Figure 1a, Lane 3), which also indicated that the palmi-
toylation we detected was on OPRM1. Since palmitoyla-
tion is important for cell function, prolonged treatment
with or high concentrations of 2-BP will affect cell viabi-
lity. In the current study, the treatment time and con-
centration of 2-BP were determined empirically so as to
inhibit receptor palmitoylation while having minimal
effect on cell viability. Thus, the 2-BP treatment para-
digm we used did not completely block receptor
palmitoylation.
Mutation of the two conserved cysteine residues
(C8.53[346] and C8.58[351]) in the C terminus of
OPRM1 does not affect palmitoylation [3]. Thus, we
predicted the only other intracellular cysteine, C3.55
(170), to be the putative palmitoylation site. To confirm
this hypothesis, each of these three cysteines was
mutated to alanine individually, and the mutants were
stably expressed in HEK cells to obtain the following:
HEKC170A, HEKC346A, and HEKC351A. Although
C170A is difficult to stably express in CHO cells [3], we
were able to successfully express a high level of C170A
in the cell membrane of HEK cells, possibly because of
differences between cell lines or our use of poly-L-lysine
during cell culture. As shown in Figure 1b, Lanes 2 and
5-6, we detected similar amounts of palmitoylated
receptor in HEKOPRM1, HEKC346A, and HEKC351A
cells. Furthermore, the amount of palmitoylated receptor
in HEKC170A cells was similar to that in 2-BP-
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pretreated HEKOPRM1 cells (Figure 1b). These results
suggest that C3.55(170) but not C8.53(346) or C8.58
(351) is indeed the palmitoylation site of OPRM1.
Our subsequent [3H]-diprenorphine saturation binding
assay using isolated cell membranes indicated that there
was no difference in the amounts of receptors in the
cell membranes of the HEKOPRM1, HEKC170A,
HEKC346A, and HEKC351A cells (membrane receptors
were expressed in HEK, HEKOPRM1, HEKC170A,
HEKC346A, and HEKC351A cells at 0.06 ± 0.05, 6.87 ±
1.14, 7.36 ± 1.10, 5.12 ± 1.67, and 6.80 ± 1.61 pmol/mg
protein respectively [Figure 1c]). Our FACS analysis
using an antibody against the HA-tag further confirmed
that there was no difference in the amounts of mem-
brane receptor between the four cell lines (Figure 1d).
Since the HA-tag was located in the receptor N-termi-
nus, and the cell membrane was not disrupted during
the analysis, the results obtained from the FACS assay
should represent the actual amounts of membrane
receptor. Lastly, immunoblotting also indicated that the
overall receptor expression levels were similar between
the four cell lines (Figure 1e). In light of these results, it
is reasonable to conclude that C3.55(170) is the major
palmitoylation site of OPRM1. For the sake of consis-
tency, we will now use “OPRM1” to refer to the wild-
type OPRM1, “C170A” to refer to the palmitoylation-
deficient mutant, and “receptor” to indicate both the
wild type and mutants.
Of note, agonist treatment did not affect receptor pal-
mitoylation when morphine and fentanyl were used to
challenge the HEKOPRM1 cells (Figure 1f). Since the
studies described here focused on how receptor palmi-
toylation influences receptor signaling, the effects of
agonists on receptor palmitoylation or other subsequent
observations are not discussed in depth.
Receptor palmitoylation stabilizes morphine-induced
signaling and receptor-Gai2 coupling
To determine the influence of palmitoylation on recep-
tor signaling, we monitored morphine-induced adenylyl
cyclase inhibition and ERK phosphorylation. Morphine-
induced adenylyl cyclase inhibition is defined by the
ability of morphine to inhibit the forskolin-induced
increase in the intracellular cAMP level. We analyzed
morphine-induced ERK phosphorylation by calculating
the percentage increase of phosphorylated ERK when
compared to basal level.
As summarized in Table 1, no difference in the affi-
nities for ligands (morphine, naloxone, and Cys2-Tyr3-
Orn5-Pen7-amide [CTOP]) was detected between
OPRM1 and C170A. For example, the KI of CTOP was
11 ± 1.4 nM in HEKOPRM1 cells, and was 9.5 ± 2.1
Figure 1 Cys170 is the palmitoylation site of OPRM1. (a) Palmitoylation assays were performed in HEK and HEKOPRM1 cells. The amounts of
palmitoylated receptor were normalized against that in HEKOPRM1 (Lane 2). 50 μM 2-BP was used to treat HEKOPRM1 for 12 h (Lane 3).
Individual steps (treatment with NEM, hydroxylamine, or btn-BMCC) were omitted to validate the assay (Lanes 4-6). (b) The palmitoylation assay
was performed in HEK, HEKOPRM1, HEKOPRM1 treated with 50 μM 2-BP for 12 h, HEKC170A, HEKC346A, and HEKC351A cells. The amounts of
palmitoylated receptor were normalized against that in HEKOPRM1 (Lane 2). (c-e) Membrane receptor levels were determined with binding assay
(c), FACS (d), and immunoblotting (e). (f) HEKOPRM1 cells were treated with PBS (C), 1 μM morphine (M) and 10 nM fentanyl (F) for 5 min.
Receptor palmitoylation was then determined. (g) HEKOPRM1, HEKOPRM1 treated with 50 μM 2-BP for 12 h, and HEKC170A cells were treated
with 1 μM morphine for 5 min. Phosphorylated ERK and total-ERK were determined by immunoblotting. One-way ANOVA with Dunnett’s test as
a post-hoc test was used for analysis. The error bars and “*” represent the standard deviations and significant changes (p < 0.05, n > 3),
respectively.
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nM in HEKC170A cells (Table 1). In addition, the
expression levels of OPRM1 and C170A in the cell
membrane were similar (Figure 1c-e). However, mor-
phine induced less signaling in HEKC170A than in
HEKOPRM1 cells. The ability of morphine to induce
adenylyl cyclase inhibition in HEKC170A was approxi-
mately 75% of that in HEKOPRM1, when maximum
inhibition was analyzed (Table 2). The ability to induce
ERK phosphorylation in HEKC170A was approximately
69% of that in HEKOPRM1 (Table 2 and Figure 1g).
Morphine also induced receptor signaling in 2-BP-trea-
ted HEKOPRM1 cells and in HEKC170A cells (Table 2
and Figure 1g). These results suggest that palmitoylation
blockage impairs receptor signaling induced by
morphine.
Both of the signaling events that we monitored are
mediated via Gai2 [12]. In addition, up-regulation and
down-regulation of Gai2 in HEKOPRM1 cells signifi-
cantly affects adenylyl cyclase inhibition and ERK phos-
phorylation induced by morphine. Thus, we thought it
likely that the impaired signaling described above was
indicative of a decrease in receptor-Gai2 coupling. We
next investigated the effect of receptor palmitoylation
on Gai2 coupling.
When we analyzed the immunoreactivity of OPRM1
and Gai2 on the cell membrane (Figure 2a), the coloca-
lization between receptor and Gai2 in HEKOPRM1
cells was more obvious than in HEKC170A cells. Similar
observations were noted in our co-immunoprecipitation
experiments (Figure 2b and 2c). When we used a Gai2
antibody to perform co-immunoprecipitation, the
amount of OPRM1 co-immunoprecipitated with Gai2
was greater than that of C170A. When HA antibody
was used to immunoprecipitate the receptor, more Gai2
was co-immunoprecipitated with OPRM1 than with
C170A. These results indicate that the interaction
between Gai2 and C170A is weaker than that between
Gai2 and OPRM1.
We further investigated the interaction between recep-
tor and Gai2 with FRET analysis. The normalized net
FRET between CFPOPRM1 and YFPGai2 was much
higher than that between CFP and YFP, suggesting that
OPRM1 and Gai2 were in close proximity of each other
(≤ 10 nm). We performed FRET analysis on the cell
membrane to exclude any possible influence from the
intracellular expression of fluorescence constructs. The
normalized net FRET between CFPOPRM1 and YFP-
Gai2 was higher than that between CFPC170A and
YFPGai2 (Figure 2d). Because 1) we kept the expression
of the fluorescence constructs, like CFPOPRMA1 and
YFPGai2 to similar levels by titrating the amounts of
plasmids used for transfection, 2) we used immunoblot-
ting to monitor expression during our studies, and 3)
we determined overall fluorescence intensities prior to
our FRET and colocalization studies, the FRET differ-
ence supports the conclusion that blockage of receptor
palmitoylation in the C170A mutant impairs Gai2
coupling.
The YFP/CFP tagged receptors had similar functions
when either FLAG- or HA-tagged. Morphine-induced
adenylyl cyclase inhibition in the cells caused transient
expression of these receptor constructs with similar KIs:
9.8 ± 1.1 nM (HA-tagged OPRM1), 10.7 ± 1.4 nM
(FLAG-tagged OPRM1), 8.9 ± 1.2 nM (CFPOPRM1),
and 9.5 ± 0.8 nM (YFPOPRM1). Thus, the FRET experi-
ments should be indicative of the functional characteris-
tics of the receptors.
Receptor palmitoylation facilitates homodimerization and
subsequent Gai2 coupling
We investigated the possible contribution of OPRM1
palmitoylation to homodimerization by performing
FRET analysis between CFPOPRM1/CFPC170A and
YFPOPRM1/YFPC170A. As indicated in Figure 3a, the
normalized net FRET between CFPOPRM1 and




Morphine KH (nM) 2.8 ± 0.56 2.2 ± 0.42
KL (nM) 155 ± 27 123 ± 31
Naloxone KI (nM) 5.1 ± 0.71 6.2 ± 1.2
CTOP KI (nM) 11 ± 1.4 9.5 ± 2.1
The affinities of receptor for ligands were determined in HEKOPRM1 and
HEKC170A cells using an agonist binding assay. One-site (KI: naloxone and
CTOP) or two-site (KH and KL: morphine) curve-fitting models were used in the
analyses with GraphPad Prism 5.0. Data were analyzed by one-way ANOVA
with post-hoc Dunnett’s test. Standard deviations are provided, and “*”
represents significant changes (p < 0.05).








KI (nM) 9.3 ± 0.89 15 ± 1.2* 14 ± 1.3*
Max. Inh.
(%)
84 ± 2.8 56 ± 5.1* 63 ± 4.3*
pERK (% of
basal)
239 ± 10 154 ± 10* 164 ± 12*
The percentage inhibition of forskolin-induced cAMP increase by various
concentrations of morphine was analyzed with GraphPad Prism 5.0. The
results are presented as the maximum inhibition (Max. Inh.) and the IC50
values (KI). ERK phosphorylation was indicated by the amount of
phosphorylated ERK after 5 min of treatment with 1 μM morphine (see blots
provided in Figure 1g). The amount of total ERK and the results under control
conditions were used for normalization. Experiments were repeated at least
four times. Data were analyzed by one-way ANOVA with post-hoc Dunnett’s
test. Standard deviations are provided, and “*” represents significant changes
(p < 0.05).
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Figure 2 Palmitoylation contributes to Gai2 coupling. (a) The colocalization between HA-tagged receptor and Gai2 was determined in
HEKOPRM1 and HEKC170A cells. Images were analyzed as described in Methods. (b) Anti-HA antibody was used to precipitate receptors in
HEKOPRM1 and HEKC170A cells. Gai2 precipitated with receptors was quantified and normalized to that in HEKOPRM1cells. (c) Co-
immunoprecipitation was performed with Anti-Gai2 antibody and the precipitated receptor was quantified. (d) CFPOPRM1 or CFPC170A was
transfected into HEK cells with YFPGai2. FRET analysis was performed. A two-tailed student t-test was used. Error bars and “*” represent the
standard deviations and significant changes (p < 0.05, n > 3 for b and c; n > 10 for a and d), respectively. IP, immunoprecipitation; IB,
immunoblotting.
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YFPOPRM1 was 0.49 ± 0.03, whereas it was 0.07 ± 0.02
between CFPC170A and YFPC170A in the cell membrane.
In addition, when the HEK cells were co-transfected with
CFPOPRM1 and YFPC170A or with CFPC170A and
YFPOPRM1, the normalized net FRETs were 0.30 ± 0.05
and 0.27 ± 0.05, respectively. The colocalization and co-
immunoprecipitation assays between HAOPRM1/
HAC170A and FLAGOPRM1/FLAGC170A confirmed the
results of the FRET assay (Figure 3b and 3c). In summary,
our colocalization, co-immunoprecipitation and FRET
Figure 3 Palmitoylation stabilizes homodimerization. (a) FRET analysis was performed after transfecting combinations of CFPOPRM1/
CFPC170A and YFPOPRM1/YFPC170A into HEK cells. (b-c) FLAGOPRM1/FLAGC170A and HAOPRM1/HAC170A were transfected into HEK cells. The
colocalization between FLAG-tagged receptor and HA-tagged receptor was determined in (b). The amounts of HA-tagged receptor precipitated
with Flag-tagged receptor were normalized against the amount of HAOPRM1 precipitated with FLAGOPRM1 and summarized in (c). One-way
ANOVA with Dunnett’s test as a post-hoc test was used for analysis. The error bars and “*” represent the standard deviations and significant
changes (p < 0.05, n > 3), respectively.
Zheng et al. BMC Cell Biology 2012, 13:6
http://www.biomedcentral.com/1471-2121/13/6
Page 6 of 18
studies suggest that the amount of the OPRM1-OPRM1
homodimer is greater than the amount of the OPRM1-
C170A dimer, and the amount of the OPRM1-C170A
dimer is greater than that of the C170A-C170A homodi-
mer, when similar levels of receptors are expressed. It is
reasonable, therefore, to suggest that the ability of C170A
to form a homodimer is lower than that of OPRM1.
Because the amounts of homodimer decreased
sequentially from Lane 1 to Lane 4 in Figure 3c, we
used FRET analysis to determine if the decrease affected
receptor-Gai2 coupling (Figure 4a). We transiently
transfected YFPGai2 with either CFPOPRM1 or
CFPC170A into HEKOPRM1 and HEKC170A cells. We
considered two caveats in these experiments and took
the following steps to ensure the success of the studies:
1) we determined that HEKOPRM1 and HEKC170A
cells expressed similar amounts of membrane receptors;
and 2) we tightly controlled transient transfection of
CFPOPRM1 and CFPC170A in order to reach similar
expression levels.
According to our hypothesis, if receptor palmitoyla-
tion affects Gai2 coupling, a similar sequential decrease
in receptor-Gai2 coupling should be observed between
OPRM1 homodimer, OPRM1-C170A dimer and C170A
homodimer. As indicated in Figure 4a, we observed that
the normalized net FRET between CFPOPRM1 and
Figure 4 Palmitoylation stabilizes Gai2 coupling. (a) The FRET between CFPOPRM1 and YFPGai2 and the FRET between CFPC170A and
YFPGai2 were determined in HEKOPRM1 and HEKC170A cells. (b-c) Colocalization between FLAGOPRM1 and Gai2 (or FLAGC170A and Gai2)
was compared in HEKOPRM1 and HEKC170A cells after transfection (b). The amounts of Gai2 precipitated with FLAGOPRM1 and FLAGC170A in
the two cell lines were compared in (c). The amount of Gai2 precipitated with FLAGOPRM1 in HEKOPRM1 cells was used for normalization. One-
way ANOVA with Dunnett’s test as a post-hoc test was used. The error bars and “*” represent the standard deviations and significant changes (p
< 0.05, n > 3), respectively.
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YFPGai2 was greater than that between CFPC170A and
YFPGai2 in both HEKOPRM1 and HEKC170A cells.
The normalized net FRET between CFPOPRM1 and
YFPGai2, as well as between CFPC170A and YFPGai2,
was greater in HEKOPRM1 than in HEKC170A. These
results suggest a positive correlation between the recep-
tor palmitoylation and Gai2 coupling.
This correlation can be explained by two potential
mechanisms. One possibility is that the homodimer’s affi-
nity for Gai2 is much higher than the monomer’s affinity
for Gai2; this mechanism is supported by a previous
report [9]. A second possibility is that the C170A mono-
mer’s affinity for Gai2 is much lower than the OPRM1
monomer’s affinity for Gai2. If the second mechanism
was the dominant one, the FRET between transiently
transfected CFPC170A and YFPGai2 would be smaller in
HEKOPRM1 cells than in HEKC170A cells, because
OPRM1’s higher affinity for YFPGai2 would result in a
higher competition for Gai2 in HEKOPRM1 than in
HEKC170A. However, our FRET analysis produced the
opposite result: the FRET between CFPC170A and YFP-
Gai2 was higher in HEKOPRM1 cells than in
HEKC170A cells (Figure 4a). These observations suggest
that the reduced receptor dimerization in the absence of
palmitoylation leads to decreased Gai2 coupling. Our
additional colocalization and co-immunoprecipitation
studies further supported this hypothesis (Figure 4b and
4c). In total, these results indicate a correlation between
receptor homodimerization and Gai2 coupling.
Receptor palmitoylation facilitates cholesterol association
in the receptor signaling complex
In order to determine the detailed mechanisms underly-
ing these phenomena, we utilized the observed interac-
tion between cholesterol and palmitoyl group in the
crystal structure of b2-AR [1]. Before we could deter-
mine the existence of a similar cholesterol-palmitoyl
interaction in the OPRM1 complex, however, we first
needed to quantify the existing cholesterol in the recep-
tor complex. Because direct detection of cholesterol
within the homodimer requires purification of the
receptor to homogeneity, and there is no guarantee that
the cholesterol-receptor association will stay intact dur-
ing purification, we instead examined the amount of
cholesterol incorporated into the receptor signaling
complex using a new method, described below.
To determine cholesterol association with the receptor
complex, we used HA-antibody to precipitate the HA-
tagged receptor. In this method, if cholesterol does
associate with the receptor complex specifically, greater
amounts of cholesterol should be precipitated by the
HA antibody when compared to immunoprecipitation
with no antibody. To avoid possible influence from the
usage of antibody, FLAG antibody was used as control
antibody, as no protein was FLAG-tagged in current
paradigm. Cholesterol association with the receptor sig-
naling complex was indicated by the additional amount
of cholesterol precipitated by the HA antibody com-
pared with that precipitated by a control antibody.
Extensive washing with lysis buffer containing Triton X-
100 and digitonin ensured the removal of cholesterol
that was nonspecifically associated with the receptor sig-
naling complex.
Using this procedure, HA antibody precipitated more
cholesterol in HEKOPRM1 cells than did FLAG anti-
body or PBS. Since the receptor was HA-tagged at the
N-terminus, any detected cholesterol in the precipitated
receptors could be identified as cholesterol associated
with receptor signaling complex. Further, in control
experiments using HEK cells, the two antibodies and
PBS precipitated similar amounts of cholesterol (Figure
5a). These results confirm that this assay detects choles-
terol associated with the receptor signaling complex.
We also noted decreased cholesterol association in
HEKC170A cells (Figure 5a). The amount of cholesterol
precipitated with the HA antibody was similar to that
precipitated with the FLAG antibody, suggesting that
the mutation on C3.55(170) contributes to the choles-
terol association. Although the assay could not distin-
guish between cholesterol that associates with the
receptor directly and cholesterol that associates with
other proteins within the signaling complex, receptor
palmitoylation appears to regulate the amount of choles-
terol that associates with the complex.
Cholesterol association facilitates homodimerization and
Gai2 coupling
Because 1) a cholesterol-palmitoyl interaction has been
suggested in the b2-AR crystal structure, and 2) we
demonstrated that receptor palmitoylation facilitates
receptor dimerization and G protein coupling of
OPRM1 (Figure 2 to Figure 4), we sought to discover
whether cholesterol has the same functions in the latter
receptor. To determine the contribution of cholesterol
association to receptor signaling, we treated the cells
with simvastatin, an HMG-CoA reductase inhibitor. We
assayed receptor dimerization and G protein coupling
with FRET, colocalization and immunoprecipitation.
The cellular cholesterol content decreased on the cell
membrane of HEKOPRM1 cells after treatment of the
cells with 0.5 μM simvastatin for 12 h. We were able to
prevent the decreases in cholesterol content by includ-
ing 20 ng/ml cholesterol during the simvastatin treat-
ment (Figure 5b). As expected, simvastatin treatment
also induced a decrease in cholesterol level on the mem-
brane of HEKC170A cells (Figure 5b).
We also assessed how cholesterol depletion influences
its association with the receptor signaling complex.
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Simvastatin treatment decreased the association of cho-
lesterol with the receptor complex, but this could be
prevented by including 20 ng/ml cholesterol in the cul-
ture medium (Figure 5c). Further, simvastatin not only
decreased the amount of cholesterol precipitated in the
“PBS” group, it also impaired the ability of the HA
antibody to precipitate more cholesterol than FLAG
antibody. Since cholesterol association was not detected
in the HEKC170A cells, simvastatin treatment had no
effect in these cells (Figure 5c).
Since simvastatin treatment decreased the cellular
cholesterol content, we used the FRET assay to
Figure 5 Palmitoylation facilitates cholesterol association. (a) Cholesterol associated with receptor complex was determined in HEK,
HEKOPRM1 and HEKC170A cells. The amount of cholesterol precipitated with PBS in HEK cells was used for normalization. (b-c) HEKOPRM1 and
HEKC170A cells were treated with PBS (Control), 0.5 μM simvastatin (Simva), or 0.5 μM simvastatin with 20 ng/ml cholesterol (Simva+Chol) for 12
h. Membrane cholesterol contents were determined in (b) as described in Methods. Cholesterol association with receptor complex was
determined in (c). One-way ANOVA with Dunnett’s test (b) or two-way ANOVA with Bonferroni’s test (a, c) was used. The error bars and “*”
represent the standard deviations and significant changes (p < 0.05, n > 3), respectively. N/S, no significance.
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determine whether cholesterol content affects receptor
dimerization and G protein coupling. The normalized
net FRET between CFPOPRM1 and YFPOPRM1 in sim-
vastatin-treated HEK cells was decreased compared to
untreated cells and could be reversed by inclusion of
cholesterol during the simvastatin treatment (Figure 6a).
A similar simvastatin-mediated decrease was observed
with CFPOPRM1 and YFPGai2 and could also be
reversed by the inclusion of cholesterol during the sim-
vastatin treatment (Figure 6b). However, the cholesterol
depletion induced by simvastatin did not affect the
homodimerization (Figure 6a) or G protein coupling of
C170A (Figure 6b). Therefore, the presence of choles-
terol within the receptor signaling complex is critical for
receptor homodimerization and Gai2 coupling.
We further illustrated the relationship between recep-
tor palmitoylation, cholesterol association, and receptor
dimerization by incubating cells with the palmitoylation
inhibitor 2-BP. We observed a decrease in cholesterol
associated with the OPRM1 signaling complex after 2-
BP treatment (Figure 7a). Because of the inhibitory
effect of palmitoylation blockage on Gai2 membrane
targeting [14], the influence of 2-BP on Gai2 coupling
was not investigated. We also saw a reduction in the
normalized net FRET between CFPOPRM1 and
YFPOPRM1 after 2-BP treatment (Figure 7b). In addi-
tion, 2-BP treatment did not affect cholesterol associa-
tion with C170A or the homodimerization of C170A,
since palmitoylation blockage in C170A already
impaired these two functions to basal levels (Figure 7).
Computational modeling suggests that palmitoyl-
cholesterol interaction stabilizes the OPRM1 homodimer
We undertook modeling studies to confirm that a speci-
fic cholesterol interaction with palmitoylated C3.55(170)
may enhance the interactions at the homodimer interface
of OPRM1. The OPRM1 model we developed for the
modeling studies reported here is a homology model that
uses the b2-AR crystal structure as a template [15]. As
mentioned in Methods, OPRM1 has two TMHs that dif-
fer in the position of helix deforming residues from the
template b2-AR (TMH2: P2.58 OPRM1 vs. P2.59 b2-AR;
TMH4: P4.59 OPRM1 vs. P4.60 b2-AR). Our Conforma-
tional Memories (CM) calculations revealed that the
location of P2.58 in OPRM1 causes the pitch of TMH2
to change after the proline such that residue 2.60 faces
into the binding pocket. This same residue position in
the b2-AR resides in the TMH2/3 interface. These results
are consistent with the conformation of TMH2 in the
CXCR4 crystal structure (CXCR4 also has a Pro at 2.58)
[16]. The TMH4 region from 4.53 to 4.58 is SSAIGLP in
OPRM1. Our CM calculations showed that the presence
of the G2.56 so close to P2.58 causes a wider turn in
TMH4 than is seen in b2-AR. The net result is that
TMH4 leans more towards TMH5. One result of this
change is the lipid exposure of residue 4.59, a key residue
Figure 6 Reducing cellular cholesterol affects homodimerization and G protein coupling. (a) HEK cells were transfected with CFPOPRM1
and YFPOPRM1 or transfected with CFPC170A and YFPC170A for 24 h. These cells were than treated with PBS (Control), 0.5 μM simvastatin
(Simva), or 0.5 μM simvastatin with 20 ng/ml cholesterol (Simva+Chol) for 12 h. The FRET was analyzed to determine the amount of homodimer.
(b) HEK cells were transfected with CFPOPRM1 and YFPGai2 or transfected with CFPC170A and YFPGai2 for 24 h. These cells were than treated
as in (a) and G protein coupling was determined with FRET. One-way ANOVA with Dunnett’s test was used. The error bars and “*” represent the
standard deviations and significant changes (p < 0.05, n > 3), respectively.
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in the TMH4 dimer interface (see below). These two key
helix changes, along with the resulting changes in helix
packing, distinguish the OPRM1 binding pocket (and
lipid face) from that of b2-AR.
Our detailed modeling procedures are described in
Methods. Figure 8a illustrates the position of cholesterol
relative to the palmitoyl and the TMH bundle. Due to
the extreme tilt of TMH3 in the TMH bundle, the intra-
cellular end of TMH3 (orange) is between the intracellu-
lar ends of TMH4 (yellow) and TMH5 (cyan). This
position of TMH3 allows the cholesterol to pack between
the C3.55(170) palmitoyl and TMH4. Figure 8b provides
an extracellular view of the final energy-minimized
OPRM1 homodimer. In the resultant dimer, cholesterol
is packed against the TMH4 interface and TMH3. The
palmitoyl at C3.55(170) is packed against the cholesterol
with TMH5, blocking cholesterol from leaving the inter-
face. Table 3 provides a summary of the resultant interac-
tion energies for the palmitoylated OPRM1 homodimer/
cholesterol complex. It is clear here that the major ener-
getic contributions to the interaction energies between
the protomers are van der Waals (VDW) energies. The
homodimer interface residues with VDW contributions
are N4.41, I4.44, C4.48, I4.51, and I4.56, with a total
energy of -14.76 kcal/mol. The cholesterol associated
with protomer A interacts with protomer B residues
R4.40, N4.41, K4.43, I4.44, and V4.47, contributing an
additional -2.44 kcal/mol, and the cholesterol associated
with protomer B contributes an additional -2.39 kcal/
mol. Thus, the total cholesterol interactions (-4.83 kcal/
mol) contribute 24.7% to the total interaction energy at
the homodimer interface (-19.59 kcal/mol), suggesting
that the interaction between cholesterol and palmitoyl
facilitates OPRM1 homodimerization
Discussion
In summary, our experimental studies suggest that a
cholesterol-palmitoyl interaction facilitates homodimeri-
zation and G protein coupling. This conclusion is
further supported by computational models of the
OPRM1 homodimer, which show that palmitoyl linked
to C3.55(170) can trap cholesterol at the interface of
OPRM1 homodimer; this subsequently stabilizes the
homodimerization. C3.55 is highly conserved in the
class A rhodopsin GPCRs, especially the peptide, opsin,
olfactory, thyrotropin-releasing hormone and melatonin
receptor families [17]. C3.55(130) on the melatonin type
1 receptor contributes to G protein activation [18]. The
critical role of the homologous residues in G protein
coupling/activation has also been confirmed in the m5
muscarinic receptor, the a1b-adrenergic receptor, the
AT1 angiotensin receptor, and the interleukin-8 recep-
tor, as summarized in the G Protein-Coupled Receptor
Data Base (GPCRDB) [17]. Although palmitoylation of
the other two opioid receptor, δ-opioid receptor and
-opioid receptor, has not been reported yet, the
Figure 7 Palmitoylation inhibitor impairs homodimerization and cholesterol association. (a) HEKOPRM1 or HEKC170A cells were treated
with 50 μM 2-BP or vehicle for 12 h, and the cholesterol associated with receptor complex was measured. (b) HEK cells were transfected with
CFPOPRM1 and YFPOPRM1 or transfected with CFPC170A and YFPC170A for 24 h. 50 μM 2-BP or vehicle was used to treat the cells for
additional 12 h. FRET was then determined. Two-way ANOVA with Bonferroni’s test (a) or student t-test (b) was used. Error bars and “*” represent
the standard deviations and significant changes (p < 0.05, n > 3), respectively.
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palmitoylation site in OPRM1 is conserved in the other
two opioid receptors: C3.55(151) in δ-opioid receptor
and C3.55(161) in -opioid receptor. The location of δ-
opioid receptors in cholesterol-rich lipid rafts and its
formation of a heterodimer OPRM1 suggests the
possible involvement of the palmitoylation on C3.55 in
its signaling [19,20].
The palmitoylation inhibitor 2-BP decreased the nor-
malized net FRET between CFPOPRM1 and YFPOPRM1
to the level of that between CFPC170A and YFPC170A
Figure 8 Computational modeling of the OPRM1 homodimer interface. (a) This figure illustrates the position of cholesterol relative to the
palmitoyl and the OPRM1 TMH bundle. The view is from lipid looking toward TMH4 (yellow). The OPRM1 model is displayed in molecular
surface view, with cholesterol (green) and palmitoyl (orange) contoured at their VDW radii. TMH3 and TMH5 are in orange and cyan, respectively.
(b) This figure illustrates an extracellular view of protomers A and B forming the OPRM1 homodimer TMH4 interface. Residues that form the
interface (N4.41, I4.44, C4.48, I4.51, A4.55, and P4.59) are contoured at their VDW radii and colored magenta. Also contoured at their VDW radii
are the palmitoyls (orange) and cholesterols (green). In this arrangement, cholesterols associated with one protomer also interact with the
opposite protomer.
Zheng et al. BMC Cell Biology 2012, 13:6
http://www.biomedcentral.com/1471-2121/13/6
Page 12 of 18
(Figure 3a and 7b). 2-BP also decreased the cholesterol
association with the signaling complex (Figure 7a). We did
not determine the influences of 2-BP on receptor signaling
and G protein coupling, because of its inhibitory effect on
the membrane targeting of the highly palmitoylated G pro-
teins [14]. Since the effects of 2-BP were consistent with
the effects of the C3.55(170) mutation, any conformational
changes other than depalmitoylation are not significant in
our current observations.
The dimerization of GPCRs, including the higher
order oligomeric state of rhodopsin, has been long
reported [21,22]. The interface of monomer GPCR has
been suggested to be too small for G protein coupling
[9]. However, the interaction between GPCR monomer
and G protein still cannot be excluded. Here, the FRET
between CFPC170A and YFPC170A was about 13% of
that between CFPOPRM1 and YFPOPRM1 (Figure 3a),
whereas the FRET between CFPC170A and YFPGai2
was about 28% of that between CFPOPRM1 and YFP-
Gai2 (Figure 4a). This difference suggests that the
receptor monomer can still interact with Gai2, though
with a lower affinity than the homodimer.
In the b2-AR crystal structure, cholesterol is found
situated at the intracellular side of the TMH1-TMH4
bundles [1]. Thus, it is probable that localization of
OPRM1 within cholesterol-enriched domains such as
lipid rafts regulates the cholesterol content within the
receptor complex and receptor signaling. Therefore, the
cholesterol-enriched lipid raft microdomain may be
essential for the ability of the cholesterol-palmitoyl
interaction to stabilize receptor homodimerization and
G protein coupling. In our studies, C3.55(170) palmitoy-
lation affected the amount of cholesterol associated with
the signaling complex. As reported previously, Gai2
anchors OPRM1 to the lipid raft microdomains. Thus,
by facilitating Gai2 coupling, cholesterol associated with
OPRM1 increases the percentage of receptor in lipid
raft microdomains.
The modeling studies reported here show that the
C3.55(170) palmitoylation site is located very near the
Class A GPCR inactive homodimer interface identified
by Guo and colleagues for dopamine D2 receptor [23].
For an OPRM1 homodimer formed at this interface, the
cholesterol associated with C3.55(170) is ideally placed
to contribute to the total energy of interaction for the
homodimer. As Lambert discusses in his recent review
[24], the interaction energies at the homodimer interface
are likely weak but sufficient to promote dimer forma-
tion transiently. We report here that the enthalpic com-
ponent of the interaction between OPRM1 homodimers
is -14.76 kcal/mol and that the presence of cholesterol
at the OPRM1 homodimer interface raises the total
interaction enthalpy to -19.59 kcal/mol. This modest
interaction energy is derived predominantly from VDW
interactions, as would be expected for the hydrophobic
residues as well as the hydrophobic cholesterols in the
homodimer interface. By identifying a consensus choles-
terol binding motif in the TMH2-TMH4 region that
predicts cholesterol binding for 44% of human class A
receptors, Hanson and co-workers suggest that specific
sterol binding is important to the structure and stability
of many GPCRs [25]. However, this consensus motif is
not present in OPRM1 and does not involve C3.55.
In conclusion, both our experimental data and computa-
tional models delineate a cascade from cholesterol-palmi-
toyl interaction to receptor homodimerization and then to
G protein coupling/activation. Conceivably, by regulating
the cholesterol-palmitoyl interaction, either by the control
of cholesterol metabolism or receptor palmitoylation, the
stability of GPCR homodimers is altered, leading to the
uncoupling of G protein. In this respect, the cellular cho-
lesterol content, specifically the cholesterol associated with
the receptor, represents an additional target through
which the signaling of GPCRs can be regulated.
Conclusions
C3.55(170) is the palmitoylation site of OPRM1
OPRM1 is highly palmitoylated. The C3.55(170) has
been indirectly suggested as the palmitoylation site, as it
Table 3 Homodimer interface interaction energies.
Interaction energies Coulombic VDW Total
kcal/mol kcal/mol kcal/mol
Protomer A, B
T4.38 -0.01 -0.03 -0.04
P4.39 0.08 -0.02 0.06
R4.40 0.30 -0.31 -0.01
N4.41 -0.32 -1.06 -1.38
I4.44 -0.02 -3.56 -3.58
I4.45 0.09 -1.22 -1.13
V4.47 -0.06 -0.24 -0.31
C4.48 0.11 -1.49 -1.38
W4.50 0.03 -0.02 0.01
I4.51 0.18 -2.77 -2.58
L4.52 0.03 -0.11 -0.08
S4.54 0.03 -0.06 -0.03
A4.55 0.21 -2.11 -1.90
I4.56 0.11 -2.42 -2.32
G4.57 -0.03 0.00 -0.04
P4.59 0.01 -0.07 -0.06
Subtotal 0.74 -15.50 -14.76
Cholesterol A, Protomer B 0.07 -2.52 -2.44
Cholesterol B, Protomer A 0.10 -2.49 -2.39
Subtotal 0.17 -5.01 -4.83
Total 0.91 -20.51 -19.59
Residues in bold are residue positions shown to be involved in the TMH4
homodimer inactive state interface of the dopamine D2 receptor [36].
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has been established that the only other two cysteines
[C7.63(346) and C7.68(351)] are not the palmitoylation
site [3]. Our current studies provide the first direct evi-
dence that C3.55(170) is the palmitoylation site of
OPRM1.
A cholesterol-palmitoyl interaction can be identified in
OPRM1 complex
A cholesterol-palmitoyl interaction has been identified
both in the b2-AR crystal structure [1] and, now, in
OPRM1. Although this is not the first identification of a
cholesterol-palmitoyl interaction in a GPCR, our studies
suggest that such interactions may be observed in the
signaling complexes of many GPCRs.
Cholesterol-palmitoyl interactions contribute to OPRM1
signaling by facilitating receptor homodimerization and G
protein coupling
Our studies also represent the first report on the contri-
butions of cholesterol-palmitoyl interaction to receptor
signaling. In addition, by the using multiple assays,
including FRET, we illustrate the mechanism underlying
these contributions. This understanding provides addi-
tional information on receptor homodimerization and G
protein coupling.
Computational modeling of OPRM1 homodimer supports
the conclusions listed above
To support the conclusions mentioned above, we gener-
ated a computational model of OPRM1 homodimer
based on the structure of other relevant GPCRs. Our
model suggests that the cholesterol-palmitoyl interaction
provides additional energy to stabilize the homodimer,
which is consistent with our other observations.
Methods
Palmitoylation assay
The palmitoylation assay was carried out as reported by
Drisdel et al. [13]. Briefly, receptor was immunoprecipi-
tated with protein G agarose beads. The beads were
then sequentially incubated with 50 mM NEM to block
free sulfhydryl groups, 1 M hydroxylamine to remove
thioester-linked palmitic acid, and 40 μM btn-BMCC to
conjugate biotin to the depalmitoylated cysteines. To
assess the receptor palmitoylation level, the amount of
conjugated biotin was determined by immunoprecipita-
tion and immunoblotting [12,26]. Protein concentrations
and receptor expression levels were measured to ensure
that equal amounts of receptor were loaded in each lane
of the gel.
Membrane purification and cholesterol assay
Cells were homogenized in 0.32 M sucrose and 10 mM
HEPES (pH 7.7). The crude lysate was then centrifuged
at 1,000 × g for 10 min at 4°C, the supernatant was col-
lected, and the pellet was re-homogenized. These pro-
cesses were repeated until the pellet appeared
translucent. The collected supernatant was centrifuged
at 100,000 × g for 60 min at 4°C. The pellet was re-sus-
pended and used to determine the cholesterol content
in cell membranes. The results were normalized against
cholesterol levels in cells under control condition. Cho-
lesterol concentrations were determined by using the
Amplex Red Cholesterol Assay Kit (Invitrogen, Carlsbad,
CA) on the cell membrane preparation according to
manufacturer’s instructions.
To determine the amount of cholesterol associated
with the OPRM1 complex, a new method was used. Cells
were first treated with lysis buffer (50 mM Tris-HCl, pH
7.5, 150 mM NaCl, 0.25% sodium deoxycholate, 0.1%
Nonidet P-40, 0.5% Triton X-100, 0.1% digitonin, 50 mM
NaF, 1 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl
fluoride, 50 mM sodium pyrophosphate, 10 mM sodium
vanadate, and 1X protease inhibitor cocktail; Roche,
Indianapolis, IN). The supernatants from the cell lysates
were divided into three equal aliquots. These aliquots
were used to perform co-immunoprecipitation with PBS
(control), HA antibody (Convance, 1:1000) (to detect
HA-tagged OPRM1 and C170A), or FLAG antibody
(Sigma, 1:1000). After antibody incubation, protein G
agarose (Invitrogen, Carlsbad, CA) was added for an
additional overnight incubation. The resulting agarose
was used to determine the amount of precipitated choles-
terol with the Amplex Red Cholesterol Assay Kit (Invi-
trogen, Carlsbad, CA). The FLAG antibody was used as a
control antibody to exclude any possible influence of
antibody usage. The greater amount of cholesterol preci-
pitated by HA antibody compared with PBS or FLAG
antibody reflects the cholesterol associated specifically
with OPRM1 signaling complex. Although this method
does not directly determine cholesterol’s interaction with
the receptor, it does specifically detect cholesterol’s inter-
action with the receptor signaling complex.
FRET
CFP and YFP were fused to the C terminus of wild-type
OPRM1 or the C170A mutant of OPRM1. YFPGai2 has
YFP inserted between residues 91 and 92 of Gai2 [27].
Throughout the studies, all FRET values are expressed
as the normalized net FRET using the following formula:
IFRET = [(ICFP × CoA) - (IYFP × CoB)]/[the square root
of (ICFP × IYFP)]. IFRET is the fluorescence intensity when
a CFP-YFP (excitation-emission) filter set is used, ICFP is
the fluorescence intensity when a CFP-CFP filter set is
used, and IYFP is the fluorescence intensity when a YFP-
YFP filter set is used. CoA was determined in the cells
transfected with only CFP constructs by the following
formula: CoA = IFRET /ICFP. CoB was determined
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similarly. Including “square root” in the formula elimi-
nates the influence from the differential expression of
CFP- and YFP-conjugated protein. Briefly, more than
twenty individual regions on the cell membrane of a sin-
gle cell were analyzed, and more than twelve individual
cells were analyzed for each sample.
OPRM1 binding assay
The amounts of receptor on the cell membrane and the
affinity of agonists for receptors were determined by
binding assay [28]. Briefly, purified cell membrane was
incubated with [3H]-diprenorphine and agonists/antago-
nists. After incubation, PEG8000 and NaCl were added
to trap the receptors on Whatman GF/B filters for final
radioactive reading. Scatchard analyses were carried out
to determine the level of wild-type or mutant OPRM1
expressed on cell membranes. To determine the affi-
nities of various ligands, the cell membranes were incu-
bated with 2 nM [3H]-diprenorphine and various
concentrations of morphine, naloxone, and CTOP (0.01
nM - 10 μM). These competition binding studies were
analyzed with one- or two-site curve-fitting models in
GraphPad 5.0.
Transient transfection
The pCMV-shuttle vector (Stratagene) was used in all
studies. cDNA generation from the receptors, Gai2, and
their fluorescence-conjugated constructs was controlled
by the CMV promoter. Transient transfections were
performed with Lipofectamine 2000 (Invitrogen) follow-
ing manufacturer’s instructions. Cells were allowed to
rest for 24 h before further treatment.
Assays based on antibodies
Immunoblotting and co-immunoprecipitation assays
were performed as described previously [26]. The same
Confocal Imager used for FRET was used to analyze
colocalization. Adenylyl cyclase inhibition was measured
as previously reported [12]. ERK phosphorylation was
determined by immunoblotting [26].
Colocalization studies were performed as reported
previously [12]. Briefly, cells were cultured on poly-
lysine-coated coverslip in six-well plates. After transient
transfection and various treatments, cells were fixed
with 2% formaldehyde for 30 min. HA, Flag, and Gai2
antibodies were used as primary antibodies (1:1000).
The confocal images were captured with a BD CARV II
Confocal Imager and a Leica DMIRE2 fluorescence
microscope. Colocalization of the fluorescence pixels
was calculated with IPlab 4.0 software (BD Biosciences-
Bioimage) and the following formula: 2 × Nyellow /(Nred
+ Ngreen), where N represents the number of pixels with
fluorescence intensity over a pre-defined threshold.
Development of the OPRM1 homodimer model
A computational model of the OPRM1 inactive state
was developed using the b2-AR crystal structure as a
template [1] with two major modifications. First, the
TMH 7/elbow/Hx8 region of the b2-AR was replaced
with that of the adenosine A2A crystal structure [29]
because the “elbow region” between TMH7 and the C
terminus Helix 8 contains only two residues (P7.57 and
D7.58). This results in an elbow region of b2-AR that is
stretched. We would not expect OPRM1 to have a simi-
lar conformation since it has three elbow residues
(D7.57 E7.58 N7.59). We therefore used the elbow con-
formation in the A2A crystal structure, which also has
three residues [29], in the OPRM1 model. Second, the
Monte Carlo/simulated annealing technique CM [30]
was used to study the conformations of three OPRM1
TMHs with important sequence divergences from the
b2-AR template: TMH2 (P2.58 OPRM1 vs. P2.59 b2-
AR), TMH4 (P4.59 OPRM1 vs. P4.60 b2-AR), and
TMH6 (CWTP OPRM1 vs. CWLP b2-AR). The CM
technique explores the low free energy conformations
possible for a helix of interest using Monte Carlo simu-
lated annealing. The method of CM, developed by Guar-
nieri and Wilson [31] and extended by Guarnieri and
Weinstein [32], efficiently and completely explores the
dihedral conformational space of a molecule, indepen-
dent of the dihedral conformation of the initial molecu-
lar structure. The CM method combines Monte Carlo
exploration of the dihedral angle space with simulated
annealing (MC/SA) to determine the range of values
that each dihedral angle is capable of reaching in a
broad temperature range. The CM method has been
expanded to allow variation of bond angles in addition
to dihedral angles [30].
In the CM calculations reported here, the backbone
dihedrals of each helix were set to the standard  (-63°)
and ψ (-41.6°) for transmembrane helices. Our estab-
lished protocol is to allow all torsion angles to vary ±
10°, and to allow a larger variation of ± 50° in regions
containing flexible areas. These flexible areas are regions
where there are known helix bending residues such as
prolines, glycines, serines and/or threonines [33]. The
OPRM1 TMH regions considered flexible were the fol-
lowing: TMH2: region of i (P2.58) to i-4 (T2.54); TMH4
region of i (P4.59) to i-4 (A4.55) and TMH6 region of i
(P6.50) to i-4 (V6.46). Individual bond angles were
allowed to vary ± 8°.
CM calculations are performed in two phases: an
exploratory phase and a biased annealing phase. In the
exploratory phase, a random walk is used to first iden-
tify the region of conformational space most probable
for each torsion angle and bond angle. Specifically, each
step consists of varying two dihedral angles and one
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bond angle chosen at random from the entire set of
variable angles. The torsion angles and bond angles are
randomly picked at each temperature and each move is
accepted or rejected using the Metropolis criterion [34].
Accepted conformations in the exploratory phase are
used to create “memories” of torsion angles and bond
angles that were accepted. This information provides a
map of the accessible conformational space of each
TMH as a function of temperature. In the biased
annealing phase, the only torsion angle and bond angle
moves attempted are those that would keep the angle in
the “populated conformational space” mapped at 310 K
in the exploratory phase.
Here, the initial temperature for each run was 3000 K
with 50,000 Monte Carlo steps applied to each torsion
or bond angle variation, with cooling in 18 steps to a
final temperature of 310 K. The biased annealing phase
for the calculations began at 749.4 K, and the cooling to
310 K was performed in 7 steps. 105 structures were
output at 310 K. The output from each TMH study was
superimposed on the corresponding template helix in
the b2-AR template that had been mutated to the
sequence of OPRM1. A helix was selected for inclusion
in the revised OPRM1 that fit in the bundle with no
VDW overlaps with residues on other TMHs.
The CM helices chosen for substitution into the TMH
bundle had the following helix bend angles, wobble
angles, and face shifts: TMH2 (35.2°, -105.8°, 40.3°),
TMH4 (14.8°, -126.1°, 25.9°), and TMH6 (30.6°, -129.9°,
45.6°). Extracellular and intracellular loops were added
using MODELLER v8.2 [35]. Energy minimizations were
performed using Macromodel and the OPLS2005 all-
atom force field (version 9.8, Schrödinger, LLC, New
York, NY). A distance-dependent dielectric, 8.0 Å
extended nonbonded cutoff, 20.0 Å electrostatic cutoff,
and 4.0 Å hydrogen bond cutoff were used. A palmitoyl
was added to C3.55(170) and a cholesterol was docked
between palmitoylated C3.55(170) and TMH3. Interac-
tive docking studies in Maestro (version 9.1, Schrödin-
ger, LLC, New York, NY) were used to orient two
OPRM1/cholesterol protomers at the symmetric TMH4
interface of mouse dark state rhodopsin [22]. In this
orientation, the OPRM1 protomers form an interface
analogous to that shown by Guo and co-workers to
characterize the inactive state homodimer interface of
the dopamine D2 receptor [36]. This interface in
OPRM1 involves N4.41, I4.44, C4.48, I4.51, A4.55, and
P4.59 on each protomer. In the resultant dimer, choles-
terol is packed against the TMH4 interface and TMH3.
The palmitoyl at C3.55(170) is packed against the cho-
lesterol and TMH5, blocking cholesterol from leaving
the interface.
The energy of the OPRM1 homodimer complex was
minimized using the same force field, dielectric, and
cutoffs as described above. In the first stage of the cal-
culation, Polak-Ribier conjugate gradient minimization
was employed until a gradient of 0.1 kcal/mol A2 was
reached. A force constant of 250 kcal/mol was used on
the loop backbone atoms. All charged residues in the
loop regions and at the ends of the TMHs that face
toward lipid headgroups were mutated to neutral forms.
Non-moving fixed atom restraints were applied to the
C-alpha atoms of TMH3 in both protomers, restraining
the protomers from moving apart. The protocol was
repeated with TMH3 non-moving fixed restraints
removed.
Macromodel was used to output the pair-wise interac-
tion energy (VDW and coulombic) for a given pair of
atoms. The nonbonded interactions are represented in
OPLS2005 (as implemented in Macromodel through
Coulomb and Lennard-Jones terms) interacting between
sites centered on nuclei. Thus, the intermolecular inter-
action energy between molecules a and b is given by the
sum of interactions between the sites on the two mole-














where a and b are collected by Macromodel as atom
sets representing all atoms of a single residue for a and
all atoms of a nearby residue for b. The residue repre-
sented by a is evaluated separately against all residues
within a 7.0Å radius of residue a. With cholesterol A
defined as group 1, and with all of the atoms of any
residue within 7.0 Å of protomers A or B defined as
group 2, the pair-wise interaction energies were calcu-
lated. The interaction energy at the homodimer interface
was calculated as the sum of the interaction energies
between protomers A and B at the homodimer interface
plus the interaction energy of cholesterol A with proto-
mer B and the interaction energy of cholesterol B with
protomer A. Cholesterols A and B were blocked from
interacting with each other by the close interactions and
steric bulk of protomer A’s TMH4 and protomer B’s
TMH4; the palmitoyls could not interact with each
other for the same reason.
Statistics
Experiments were repeated at least four times (with
more than twelve individual cells used for image analy-
sis). Data were analyzed and compared by one-way
ANOVA with Dunnett’s test as a post-hoc test for com-
parisons, or by two-way ANOVA with the Bonferroni’s
test as a post-hoc test. Error bars and “*” represent the
standard deviations and significant changes (p < 0.05),
respectively.
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